669 related articles for article (PubMed ID: 32193249)
1. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
2. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Wong MG; Perkovic V; Chalmers J; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; MacMahon S; Mancia G; Marre M; Matthews D; Neal B; Poulter N; Rodgers A; Williams B; Zoungas S;
Diabetes Care; 2016 May; 39(5):694-700. PubMed ID: 27006512
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
4. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
5. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
8. New insights from ADVANCE.
Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
[TBL] [Abstract][Full Text] [Related]
9. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
[TBL] [Abstract][Full Text] [Related]
10. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; Woodward M; Hamet P; Harrap SB; Poulter N; Chalmers J;
J Am Coll Cardiol; 2010 Nov; 56(23):1908-13. PubMed ID: 21109113
[TBL] [Abstract][Full Text] [Related]
11. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
12. The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Lee AK; Woodward M; Wang D; Ohkuma T; Warren B; Sharrett AR; Williams B; Marre M; Hamet P; Harrap S; Mcevoy JW; Chalmers J; Selvin E
J Clin Endocrinol Metab; 2020 Jan; 105(1):152-62. PubMed ID: 31588504
[TBL] [Abstract][Full Text] [Related]
13. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
14. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
van Steen SC; Woodward M; Chalmers J; Li Q; Marre M; Cooper ME; Hamet P; Mancia G; Colagiuri S; Williams B; Grobbee DE; DeVries JH;
Diabetologia; 2018 Apr; 61(4):780-789. PubMed ID: 29308539
[TBL] [Abstract][Full Text] [Related]
15. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
Woodward M; Patel A; Zoungas S; Liu L; Pan C; Poulter N; Januszewicz A; Tandon N; Joshi P; Heller S; Neal B; Chalmers J
Diabetes Care; 2011 Dec; 34(12):2491-5. PubMed ID: 21972410
[TBL] [Abstract][Full Text] [Related]
16. Intensive glycemic control and cardiovascular disease: an update.
Brown A; Reynolds LR; Bruemmer D
Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
18. ADVANCE: breaking new ground in type 2 diabetes.
Chalmers J; Perkovic V; Joshi R; Patel A
J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Poulter NR
J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K
Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
